AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 241 min read$MAIA

Guerrero Ramiro purchased $16K of MAIA

Guerrero Ramiro purchased 11,899 shares of MAIA Biotechnology, Inc. (MAIA) at $1.37 on 2026-08-20.

Original reporting
SEC EDGAR · Guerrero Ramiro
Published Aug 24, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MAIA
Neutral
high confidence
Mentioned
$MAIA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MAIANeutralLow
01

Why it matters

The director's purchase modestly raises his ownership, offering limited insight into company prospects.

02

Market read

Minor insider purchase with negligible effect on MAIA's stock price.

03

What to watch

Potential upcoming clinical trial data may be the real driver, not the purchase itself.

Relevance 4/10Novelty 4/10Timing: filed 2026-08-24

Background

Form 4 filing discloses insider transactions; used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$MAIANeutralHigh confidence
Context

Director Guerrero Ramiro bought 11,899 shares at $1.37, increasing his stake to 600,117 shares.

Expected impact

Minimal short-term price movement expected.

Evidence & confidence

Purchase amount (~$16k) is trivial for a listed biotech; unlikely to move price materially.

Market effects

Sector

No immediate sector impact; insider activity typical for biotech.

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider buying could hint at upcoming positive news, but size is too small to be meaningful.

Key entities

  • Company
    MAIA Biotechnology, Inc.

    US-listed biotech company.

  • Insider
    Guerrero Ramiro

    Director of MAIA.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MAIA insider trading history →

Related articles

OCT 7
$MAIAMedAI 8/10

MAIA Completes THIO-101 Part C Enrollment; Phase 3 Enrollment Hits 65%

MAIA Biotechnology (MAIA) announced completing enrollment for Part C of its Phase 2 THIO-101 trial and 65% completion for its Phase 3 THIO-104 trial, both evaluating ateganosine in NSCLC. The company reported a 90.5% interim disease control rate for the combination therapy. MAIA aims to enroll 100 patients in THIO-104 by 2026, with an interim analysis planned for 2027. The FDA granted Fast Track designation to ateganosine in July 2025. MAIA shares are up 0.85% at $1.20.

rttnews.com2 min
OCT 7
$MAIAMedAI 9/10

MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer

MAIA Biotechnology (NYSE American: MAIA) reported milestones in its Phase 2 and Phase 3 trials for ateganosine, a telomere-targeting agent for non-small cell lung cancer (NSCLC). Enrollment is complete for Part C of the Phase 2 trial, with 90.5% interim disease control reported. The Phase 3 trial has reached 65% of its 100-patient enrollment target. The FDA granted Fast Track designation to ateganosine in July 2025.

globenewswire.com2 min